GRI Bio Says FDA Grants Orphan Drug Designation To GRI-0621 For Treatment Of Idiopathic Pulmonary Fibrosis, Irreversible And Ultimately Fatal Lung Disease

Loading news article.

GRI Bio Says FDA Grants Orphan Drug Designation To GRI-0621 For Treatment Of Idiopathic Pulmonary Fibrosis, Irreversible And Ultimately Fatal Lung Disease | WAPE

GRI Bio Says FDA Grants Orphan Drug Designation To GRI-0621 For Treatment Of Idiopathic Pulmonary Fibrosis, Irreversible And Ultimately Fatal Lung Disease

Article summary

Related companies

Comments —